Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT)

Bone Marrow Transplantation
B BjörkstrandG Gahrton

Abstract

The purpose of this study was to evaluate the effect of alpha-IFN maintenance treatment after autologous stem cell transplantation (ASCT) for multiple myeloma in a retrospective registry analysis. 473 patients with multiple myeloma who received IFN maintenance treatment ASCT were compared with 419 patients who did not receive IFN-treatment. Patients who were evaluable for response and in complete or partial remission at 6 months after ASCT were eligible, after excluding patients with graft failure. Cox proportional hazards assumptions were checked and handled by stratification. The prognostic variables unevenly distributed between the two groups were statistically corrected for in the Cox analysis. 391 patients reached complete remission (CR) after ASCT (203 in the IFN group and 188 in the no-IFN group) and 501 were in partial remission (PR, IFN 270, no-IFN 231). Overall survival (OS) and progression-free survival (PFS) were significantly better in the IFN-group (OS, 78 vs 47 months, P = 0.007, and PFS, 29 vs 20 months, P = 0.006, respectively). The difference in OS and PFS was most strongly pronounced in the PR patients. 209 patients have died (IFN, 84; no-IFN, 125). Progressive myeloma was the cause of death in 94% of the IFN...Continue Reading

References

Feb 3, 1979·Lancet·H MellstedtH Strander
May 1, 1995·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H LudwigH L Seewann
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D PeestB Göbel
Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S E SalmonB Barlogie
Jan 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M R CooperC Schiffer
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H LudwigB G Durie
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B ZeeJ Pater

❮ Previous
Next ❯

Citations

Oct 14, 2004·Springer Seminars in Immunopathology·Norbert-Claude Gorin
Sep 28, 2002·Blood Reviews·Jean-Luc Harousseau, Michel Attal
Jun 13, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H LudwigG P Browman
Aug 10, 1999·Critical Reviews in Oncology/hematology·G Gahrton, B Björkstrand
Dec 12, 2001·British Journal of Haematology·UNKNOWN UK myeloma forum. British Committee for Standards in Haematology
Jan 25, 2003·British Journal of Haematology·Juan José LahuertaUNKNOWN Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Médula Osea
Sep 6, 2000·Journal of Internal Medicine·G Gahrton, B Björkstrand
Mar 6, 2003·Reviews in Clinical and Experimental Hematology·Jean-Luc Harousseau
May 2, 2002·Anti-cancer Drugs·S Zweegman, P C Huijgens
May 6, 2010·Haematologica·Mary B DrakeUNKNOWN European Group for Blood and Marrow Transplantation and the European Leukemia Net
Sep 29, 2005·Hematology·Bo Björkstrand
Apr 14, 2006·Expert Opinion on Biological Therapy·Michael Y ShapiraShimon Slavin
Sep 24, 2004·International Journal of Cancer. Journal International Du Cancer·R García-SanzJ F San Miguel
Jan 30, 2015·Nihon rinsho. Japanese journal of clinical medicine·Ken Takase, Toshihiro Miyamoto
Oct 20, 2005·Clinical Lymphoma & Myeloma·Jean-Luc Harousseau, Philippe Moreau
Nov 4, 2004·European Journal of Haematology·Yutaka TsutsumiNobuo Masauzi
Jan 18, 2006·British Journal of Haematology·Alastair SmithUNKNOWN British Committee for Standards in Haematology
Nov 11, 2009·Pediatric Blood & Cancer·Jeremy WhelanMark Bernstein
Jul 10, 2003·Hematology·S A Schey
May 5, 2004·Seminars in Oncology·Jonathan Kaufman, Sagar Lonial
Jan 21, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Theresa HahnPhilip L McCarthy
Jan 18, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·William MatsuiConstantine Mitsiades
Jul 21, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Shubham Pant, Edward A Copelan
Dec 15, 2010·Seminars in Nephrology·Eliot C Heher, Thomas R Spitzer
Sep 16, 2008·Best Practice & Research. Clinical Haematology·Jacalyn Rosenblatt, David Avigan
May 19, 2012·Seminars in Oncology·David AviganDonald Kufe
Jul 20, 2005·Best Practice & Research. Clinical Haematology·Jean-Luc HarousseauHervé Avet-Loiseau
Nov 13, 2007·Hematology/oncology Clinics of North America·Jean-Luc Harousseau
Nov 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Paul FermandUNKNOWN Group Myelome-Autogreffe
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ashraf BadrosGuido Tricot
May 2, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henk M LokhorstUNKNOWN Dutch-Belgian Hemato-Oncology Cooperative Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.